Semaglutide Contraindications & Medical Screening

Last reviewed: May 16, 2026 Last updated: May 16, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide is contraindicated in specific patient populations due to serious safety risks. Absolute contraindications include personal or family history of medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN2), where GLP-1 agonists may increase risk of thyroid C-cell tumors.

Before starting semaglutide therapy, comprehensive medical screening is essential to identify risk factors, evaluate organ function, and assess individual predispositions. PlexusDx supports precision-wellness by combining clinical assessment with genetic insights to help your provider make informed treatment decisions tailored to your unique health profile.

Absolute Contraindications That Exclude Semaglutide Use

Absolute contraindications are medical conditions where semaglutide use is unsafe and must be avoided. Personal or family history of medullary thyroid carcinoma (MTC) is the strongest contraindication. GLP-1 receptor agonists activate GLP-1 receptors on thyroid C-cells, potentially promoting growth of C-cell tumors or increasing recurrence risk in MTC survivors.

Multiple Endocrine Neoplasia syndrome type 2 (MEN2a and MEN2b) is also absolute contraindication. Patients with MEN2 mutations carry inherited risk for MTC and other neuroendocrine cancers. Semaglutide is also contraindicated in pregnancy due to potential fetal risk. Animal studies showed developmental effects; human safety data remain limited.

Relative Contraindications and Risk Factors Requiring Provider Evaluation

Relative contraindications are conditions where semaglutide may be used with careful monitoring and risk-benefit assessment by your healthcare provider. Pancreatitis history, gallbladder disease, severe renal impairment, and certain cardiac conditions require individual evaluation before initiating therapy. Provider judgment and close follow-up are essential.

Medical Condition	Clinical Consideration
Personal history of pancreatitis	Semaglutide may increase acute pancreatitis risk; requires close monitoring and patient symptom awareness
Gallbladder disease / cholelithiasis	Rapid weight loss with GLP-1 therapy increases cholecystitis and choledocholithiasis risk; imaging may be warranted
Severe renal impairment (eGFR <15)	Limited pharmacokinetic data; dose adjustment or avoidance may be necessary; requires nephrologist consultation
Diabetic retinopathy (Type 2 diabetes)	Rapid glycemic control improvement may worsen existing retinopathy; ophthalmology clearance recommended before initiating therapy
Thyroid nodules / thyroid disease	Baseline thyroid ultrasound and TSH evaluation needed; annual monitoring required due to GLP-1 effects on C-cells
Heart failure (NYHA Class III-IV)	Limited safety data in advanced heart failure; cardiology evaluation essential before starting semaglutide

Essential Biomarkers and Lab Assessment Before Starting Therapy

Comprehensive baseline laboratory testing identifies organ function, metabolic status, and hidden risk factors before semaglutide initiation. Key biomarkers include fasting glucose, HbA1c, comprehensive metabolic panel (electrolytes, kidney function, liver enzymes), lipid panel, amylase, lipase, and TSH. Calcitonin testing may be considered in patients with personal or family thyroid history.

Renal function assessment via eGFR or creatinine clearance is critical because GLP-1 agonists can affect renal perfusion and increase risk of acute kidney injury in susceptible patients. Liver function tests detect hepatic impairment that may affect drug metabolism. Thyroid-stimulating hormone (TSH) and free T4 establish baseline thyroid status; annual monitoring is recommended during semaglutide therapy.

Who Should Not Take Semaglutide: Clinical Framework for Provider Assessment

Your healthcare provider evaluates multiple factors beyond formal contraindications: age, comorbidities, medication interactions, socioeconomic factors, and ability to tolerate gastrointestinal side effects. Pregnant or breastfeeding patients should avoid semaglutide. Patients with unstable psychiatric conditions, severe malabsorption, or active cancer require individualized risk-benefit discussion with their provider.

Safe semaglutide use requires ongoing communication with your healthcare team. Report any personal or family history of thyroid cancer, MEN2 syndromes, pancreatitis, or kidney disease before starting. If side effects emerge or medical conditions change during therapy, promptly contact your provider. Regular monitoring supports early identification of adverse effects and enables timely dose adjustments.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context regarding genetic predispositions in peptide metabolism and GLP-1 receptor pathways. Variants in genes like GLP1R, GIPR, FTO, and MC4R can reveal how your body may respond to GLP-1 agonist therapy. This information should be interpreted with your qualified healthcare provider to support more informed treatment decisions alongside clinical screening.

The genetic test reveals predispositions in peptide genetic pathways—not pharmacogenomic drug metabolism profiles or exact medication response. Understanding your genetic background in GLP-1 signaling, appetite regulation, and metabolic function can support a more personalized conversation with your provider about whether semaglutide aligns with your biology and health goals.

When combined with comprehensive medical screening, genetic predisposition insights empower you and your provider to evaluate semaglutide candidacy holistically. If you have contraindications or relative risk factors, your provider may recommend alternative GLP-1 compounds, different weight-loss strategies, or careful monitoring protocols. Genetic context and clinical assessment together support safer, more tailored care.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.